VivoSeq
Other

IVF

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

IVF is an early-stage landscape with 0 programs across 2 companies. The most active players are Changchun GeneScience Pharmaceutical Co., Ltd., Nora Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

0 programs

PreclinicalN

Nora Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Unknown status7 · 54%
Completed4 · 31%
Withdrawn2 · 15%

Clinical Trials

Trial Activity

13 trials

Luteal Phase FSH in the IVF Poor Responder
Completed·UUniversity of Pennsylvania·Phase 4·NCT00225433·20 enrolled
Short Versus Long Protocol for IVF and IVF+ICSI
Completed·PPeter Hornnes, MD, DMSc·Phase 4·NCT00756028·1,099 enrolled
Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)
Completed·NNora Therapeutics, Inc.·Phase 2·NCT01978561·40 enrolled
Protocols of IVF/ICSI in Poor Responders
Completed·—·Phase 3·NCT04356105·132 enrolled
RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders
Withdrawn·WWeill Medical College of Cornell University·Phase 4·NCT01577199
Injection Free IVF
Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT04850261
FSH Followed by HMG vs FSH Plus HMG in IVF
Unknown status·MMansoura University·Phase 4·NCT04385342·530 enrolled
Antagonist Protocol in IVF
Unknown status·WWoman's Health University Hospital, Egypt·Phase 2·NCT02335736·200 enrolled
Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF
Unknown status·BBioroma·Phase 4·NCT02070198·120 enrolled
Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
Unknown status·UUniversitair Ziekenhuis Brussel·Phase 4·NCT00954811·40 enrolled
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET
Unknown status·Changchun GeneScience Pharmaceutical Co., Ltd. logoChangchun GeneScience Pharmaceutical Co., Ltd.·Phase 3·NCT03071172·252 enrolled
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
Unknown status·—·Phase 3·NCT03240159·120 enrolled
Effects of SNP of GnRH Receptor Genes in IVF Patients
Unknown status·—·N/A·NCT02979886·1,500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)